Literature DB >> 16318954

Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes.

Ashish Dhir1, Pattipati S Naidu, Shrinivas K Kulkarni.   

Abstract

Cyclooxygenase (COX) is reported to play a significant role in neurodegeneration. Recent studies have shown that chronic ethanol administration up-regulates cyclooxygenase expression. In the present study we examined the effect of nimesulide (a preferential COX-2 inhibitor), rofecoxib (a highly selective COX-2 inhibitor) or naproxen (a non-selective COX-inhibitor displaying high affinity towards the COX-1 isoenzyme) on alcohol-induced withdrawal symptoms. Mice were made physically dependent on alcohol by the chronic administration of ethanol (2 g/kg of 10% v/v), intragastrically, twice on day 1 and then once-daily on successive days for a total of 7 days. Nimesulide [2.5 mg/kg, intraperitoneally (i.p.)], rofecoxib (2 mg/kg, i.p.) or naproxen (7 mg/kg, i.p.) were administered daily for 7 days before administering alcohol intragastrically. After 24 hours of the last alcohol administration, the treatments were reversed and the mice were tested for withdrawal, so that the animals that had received COX-inhibitors followed 30 minutes later by ethanol on days 1-7 were challenged with saline. Similarly, the animals which received saline followed 30 minutes later by ethanol received only saline. Behavioural analysis revealed hyperlocomotor activity, increased anxious response and increased hyperalgesia in mice. Also, alcohol withdrawal decreased the threshold for Pentylenetetrazole-(PTZ)-induced convulsions. Pretreatment with COX-inhibitors rofecoxib (2 mg/kg, i.p.) or nimesulide (2.5 mg/kg, i.p.) displayed significant protection against ethanol-induced withdrawal symptoms, while naproxen (7 mg/kg, i.p.) was not effective in reversing alcohol-induced withdrawal symptoms. The results of the present study suggest strongly the possible role of cyclooxygenases, particularly COX-2 inhibitors, on ethanol-induced withdrawal symptoms and the potential use of COX-2 inhibitors in their prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318954     DOI: 10.1080/13556210500352964

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  6 in total

1.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

2.  Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition.

Authors:  Supriti Samantaray; Varduhi H Knaryan; Kaushal S Patel; Patrick J Mulholland; Howard C Becker; Naren L Banik
Journal:  Brain Res       Date:  2015-06-20       Impact factor: 3.252

3.  COX-2 Inhibition Antagonizes Intra-Accumbens 2-Arachidonoylglycerol-Mediated Reduction in Ethanol Self-Administration in Rats.

Authors:  Francisco J Pavon; Ilham Polis; David G Stouffer; Marisa Roberto; Rémi Martin-Fardon; Fernando Rodriguez de Fonseca; Loren H Parsons; Antonia Serrano
Journal:  Alcohol Clin Exp Res       Date:  2020-10-03       Impact factor: 3.455

4.  Acute illness-induced behavioral alterations are similar to those observed during withdrawal from acute alcohol exposure.

Authors:  Laura Richey; Tamara L Doremus-Fitzwater; Hollin M Buck; Terrence Deak
Journal:  Pharmacol Biochem Behav       Date:  2012-08-17       Impact factor: 3.533

5.  Chronic inflammatory pain drives alcohol drinking in a sex-dependent manner for C57BL/6J mice.

Authors:  Waylin Yu; Lara S Hwa; Viren H Makhijani; Joyce Besheer; Thomas L Kash
Journal:  Alcohol       Date:  2018-10-06       Impact factor: 2.405

6.  Antidepressant activity of curcumin: involvement of serotonin and dopamine system.

Authors:  Shrinivas K Kulkarni; Mohit Kumar Bhutani; Mahendra Bishnoi
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.